文献速递肺外科

结直肠癌肺转移瘤切除术后肺部监测:利用临床病理危险因素指导策略

Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-07-24

该单中心回顾性研究纳入197例结直肠癌肺转移瘤切除术患者,52.3%在术后中位9.51个月出现后续肺转移。KRAS改变(OR 3.073)和TP53改变(OR 3.109)与术后6个月内肺转移诊断风险相关,APC改变(OR 0.218)具保护作用;初始肺转移诊断后3个月内接受全身治疗者早期肺复发风险亦较高(OR 2.105,95%CI 0.971-4.563,P=0.059)。

要点

  • KRAS改变者术后6个月内肺转移风险升高(OR 3.073,95%CI 1.363-6.926,P=0.007)。
  • TP53改变者术后6个月内肺转移风险升高(OR 3.109,95%CI 1.318-7.341,P=0.010)。
  • APC改变者术后6个月内肺转移风险降低(OR 0.218,95%CI 0.080-0.598,P=0.003)。

核心结论

  • 携带KRAS改变、TP53改变且无APC改变的患者,以及初始肺转移诊断后接受化疗的患者,肺转移瘤切除术后出现早期肺复发。
  • 作者认为这些人群可从术后早期肺部影像监测中获益,胸部监测方案应基于以患者为中心的临床病理和基因组危险因素。

研究设计与样本

  • 单中心前瞻性维护外科数据库的回顾性分析。
  • 纳入197例接受结直肠癌肺转移瘤切除术的患者。
  • 按索引肺切除术后6个月内诊断后续肺转移进行分层,采用多变量建模评估危险因素。

主要发现

  • 197例患者中52.3%(n=103)出现后续肺转移,中位时间为索引转移瘤切除术后9.51个月。
  • KRAS改变与索引转移瘤切除术后6个月内肺转移诊断风险相关(OR 3.073,95%CI 1.363-6.926,P=0.007)。
  • TP53改变与索引转移瘤切除术后6个月内肺转移诊断风险相关(OR 3.109,95%CI 1.318-7.341,P=0.010)。
  • APC改变与索引转移瘤切除术后6个月内肺转移诊断风险降低相关(OR 0.218,95%CI 0.080-0.598,P=0.003)。
  • 初始肺转移诊断后3个月内接受全身治疗者早期肺复发风险较高(OR 2.105,95%CI 0.971-4.563,P=0.059)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Appropriately selected patients clearly benefit from resection of colorectal cancer (CRC) pulmonary metastases (PMs). However, there remains equipoise surrounding optimal chest surveillance strategies following pulmonary metastasectomy. We aimed to identify risk factors that may inform chest surveillance in this population. METHODS: Patients who underwent CRC pulmonary metastasectomy were identified from a single institution's prospectively maintained surgical database. Clinicopathologic and genomic characteristics were collected. Patients were stratified by diagnosis of subsequent PM within 6 months of the index lung resection. Multivariate modeling was used to evaluate risk factors. RESULTS: A total of 197 patients met the study's inclusion criteria, of whom 52.3% (n = 103) developed subsequent PM, at a median of 9.51 months following the index metastasectomy. Patients with KRAS alterations (odds ratio [OR], 3.073; 95% confidence interval [CI], 1.363-6.926; P = .007), TP53 alterations (OR, 3.109; 95% CI, 1.318-7.341; P = .010) were found to be at risk of PM diagnosis within 6 months of the index metastasectomy, while those with an APC alteration (OR, .218; 95% CI, 0.080-0.598; P = .003) were protected. Moreover, patients who received systemic therapy within 3 months of the initial PM diagnosis also were more likely to develop early lung recurrence (OR, 2.105; 95% CI, 0.971-4.563; P = .059). CONCLUSIONS: Patients with KRAS alterations, TP53 alterations, and no APC alterations developed early recurrence in the lung following pulmonary metastasectomy, as did those who received chemotherapy after their initial PM diagnosis. As such, these groups benefit from early lung imaging after metastasectomy, as chest surveillance protocols should be based on patient-centered clinicopathologic and genomic risk factors.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Deboever N, Bayley EM, Eisenberg MA, et al. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy. J Thorac Cardiovasc Surg. 2023. PMID: 37495170. doi:10.1016/j.jtcvs.2023.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。